US4450877A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical preparations in solid unit dosage form
Assignee: Sanofi Aventis Deutschland GmbH
•
Filing: 1982-09-08
•
Granted: 1984-05-29
•
Expires: 2002-09-08
Abstract
Abstract A process for the manufacture of pharmaceutical preparations in hard capsule form and a capsule filling machine equipped with a detector system and a filling head suitable for dosing a liquid.
Inventors
- 👤 Stephen E. Walker
- 👤 Keith Bedford
- 👤 Terence Eaves
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 20:59
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/48; A61K9/4841; A61K9/4858; A61J; A61J3/00; A61J3/07; A61J3/071; A61J3/074; A61K9/4833; A61K9/4866
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
72 words
A process for the manufacture of a pharmaceutical preparation in unit dosage form, which comprises the steps of preparing a liquid carrier containing an active ingredient and a liquid which solidifies or gels sufficiently to lose its liquid flow properties said liquid carrier being a thixotropic gelling agent, and dosing said liquid carrier containing the active ingredient in its liquid form into a rigid shell suitable for administration as a dosage unit.
Claim 2
Dependent Claim
72 words
A process for the manufacture of a pharmaceutical preparation in unit dosage form, which comprises the steps of preparing a liquid carrier containing an active ingredient and a liquid which solidifies or gels sufficiently to lose its liquid flow properties said liquid carrier being a thixotropic gelling agent, and dosing said liquid carrier containing the active ingredient in its liquid form into a rigid shell suitable for administration as a dosage unit.
Claim 3
Dependent Claim
45 words
The process of claim 1, wherein the liquid carrier comprises a polyethylene glycol having a molecular weight in the range of from 1000 to 6000, a mixture of two or more such polyethylene glycols or a mixture of one or more such polyethyleneglycols with polyvinylacetate.
Claim 4
Dependent Claim
18 words
The process of claim 1, wherein the thixotropic gelling agent is hydrogenated castor oil or colloidal silicon dioxide.
Claim 5
Dependent Claim
17 words
The process of claim 1, wherein the rigid shell is the body of a hard gelatin capsule.
Claim 6
Dependent Claim
18 words
The process of claim 1, wherein the dosing takes place in a high-speed hard gelatin capsule filling machine.
Claim 7
Dependent Claim
41 words
The process defined in claim 1 wherein the liquid carrier containing the active ingredient is dosed into the rigid shell using a capsule filling machine which is equipped with a detector system and a filling head suitable for dosing a liquid.
Claim 8
Dependent Claim
47 words
The process defined in claim 1 wherein the liquid carrier containing the active ingredient is dosed into the rigid shell using a capsule filling machine which is equipped with a detector system and a refillable syringe, a peristaltic pump or a precision shot dispenser as filling head.
Claim 9
Dependent Claim
31 words
The process defined in claim 1 which comprises detecting the presence or absence of a shell to receive a dosage unit before dosing the shell with liquid carrier and active ingredient.
Claim 10
Dependent Claim
67 words
A process for the manufacture of a pharmaceutical preparation in unit dosage form, which comprises the steps of dispersing an active ingredient into a liquid carrier which is a thixotropic gelling agent and maintained in its liquid form, dosing said liquid carrier containing the active ingredient into a rigid shell suitable for administration as a dosage unit, and thereafter permitting said carrier in said shell to solidify.
Claim 11
Dependent Claim
67 words
A process for the manufacture of a pharmaceutical preparation in unit dosage form, which comprises the steps of dispersing an active ingredient into a liquid carrier which is a thixotropic gelling agent and maintained in its liquid form, dosing said liquid carrier containing the active ingredient into a rigid shell suitable for administration as a dosage unit, and thereafter permitting said carrier in said shell to solidify.
Claim 12
Dependent Claim
45 words
The process of claim 18, wherein the liquid carrier comprises a polyethylene glycol having a molecular weight in the range of from 1000 to 6000, a mixture of two or more such polyethylene glycols or a mixture of one or more such polyethyleneglycols with polyvinylacetate.
Claim 13
Dependent Claim
18 words
The process of claim 18, wherein the thixotropic gelling agent is hydrogenated castor oil or colloidal silicon dioxide.
Claim 14
Dependent Claim
15 words
A pharmaceutical preparation in unit dosage form manufactured by the process defined by claim 1.
References Cited (Backward Citations)
US1378536A
Cited
US2987082A
Cited
DE1617362A1
Cited
DE1933562A1
Cited
DE2157201A1
Cited
US3927196A
Cited
GB1380009A
Cited
DE2340010A1
Cited
US3807464A
Cited
DE2301664A1
Cited
GB1427881A
Cited
DE2357503A1
Cited
GB1442951A
Cited
US3935885A
Cited
US3903939A
Cited
DE2546371A1
Cited
DE2546577A1
Cited
GB1560406A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-05-29 | 1987-11-28 | 1988-05-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-05-29 | 1991-11-28 | 1992-05-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-05-29 | 1995-11-28 | 1996-05-29 | $7700.00 | Window Closed / Lapsed |